Mind Medicine (MindMed) I... (MNMD)
6.29
-0.10 (-1.64%)
At close: Jan 15, 2025, 9:35 AM
Company Description
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology.
The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.
It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder.
The company is headquartered in Vancouver, Canada.
Mind Medicine (MindMed) Inc.
| Country | CA |
| IPO Date | Nov 15, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Robert Barrow |
Contact Details
Address: 1055 West Hastings Street Vancouver, BC CA | |
| Website | https://www.mindmed.co |
Stock Details
| Ticker Symbol | MNMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001813814 |
| CUSIP Number | 60255C109 |
| ISIN Number | CA60255C8850 |
| Employer ID | 00-0000000 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Robert Barrow | Chief Executive Officer & Director |
| Mark R. Sullivan J.D. | Chief Legal Officer & Corporate Secretary |
| Carrie F. Liao CPA, CGMA | Vice President & Chief Accounting Officer |
| Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer |
| Dr. Francois P. Lilienthal M.B.A., M.D. | Chief Commercial Officer |
| Dr. Gregg Pratt Ph.D. | Chief Regulatory & Quality Assurance Officer |
| Dr. Miriam Halperin Wernli B.A., M.A., M.B.A., MBA, Ph.D. | Executive President |
| Dr. Scott M. Freeman M.D. | Co-Founder & Clinical Advisor |
| Leonard Latchman | Co-founder |
| Stephanie Fagan | Chief Corporate Affairs Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 8-K | Current Report |
| Dec 27, 2024 | 4 | Filing |
| Dec 27, 2024 | 4 | Filing |
| Dec 27, 2024 | 4 | Filing |
| Dec 27, 2024 | 4 | Filing |
| Dec 16, 2024 | 8-K | Current Report |
| Dec 05, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 07, 2024 | 10-Q | Quarterly Report |